Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
0
FDA Orange Book
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Acid, Fusidic
2. Fucithalmic
3. Fusidate, Silver
4. Fusidin
5. Silver Fusidate
6. Sodium Fusidate
7. Stanicide
1. Fusidine
2. 6990-06-3
3. Ramycin
4. Fucithalmic
5. Fusidate
6. Fucidic Acid
7. Fucidin Acid
8. Fucidin
9. Flucidin
10. Fucidate
11. Taksta
12. Sodium Fusidate
13. Sq 16,603
14. (-)-fusidic Acid
15. (2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic Acid
16. Anhydrous Fusidic Acid
17. Cem-102
18. Nsc-56192
19. Sq 16603
20. Mls001332649
21. Chebi:29013
22. 59xe10c19c
23. Smr000857101
24. Sq-16603
25. (2e)-2-[(3r,4s,5s,8s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic Acid
26. Acide Fusidique
27. Acido Fusidico
28. Fusidinic Acid
29. Acidum Fusidicum
30. Mfcd00865135
31. (-)-16beta-acetoxy-3alpha,11alpha-dihydroxyfusida-17(20)z,24-diene-21-oic Acid
32. (2z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic Acid
33. (2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-hept-5-enoic Acid
34. (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic Acid
35. (z)-2-((3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethyldodecahydro-1h-cyclopenta[a]phenanthren-17(2h,10h,14h)-ylidene)-6-methylhept-5-enoic Acid
36. Fusidic Acid (usan/inn)
37. Fusidic-acid
38. Fusidate Acid
39. 1qca
40. Fusidicacid
41. C.a.s. 62,602
42. Prestwick2_000390
43. Fusidic Acid [mi]
44. Fusidic Acid [inn]
45. Fusidic Acid [usan]
46. Schembl25646
47. Mls001332650
48. Mls002207094
49. Unii-59xe10c19c
50. Acide Fusidique [inn-french]
51. Acido Fusidico [inn-spanish]
52. Acidum Fusidicum [inn-latin]
53. Fusidic Acid [who-dd]
54. Cem102
55. Chembl374975
56. Dtxsid0023086
57. Fusidic Acid [usan:inn:ban]
58. Bdbm58924
59. Cid_3000226
60. Gtpl10815
61. Hms2235b11
62. Fusidic Acid [ep Impurity]
63. Act03304
64. Ex-a3797
65. Fusidic Acid [ep Monograph]
66. Hy-b1350
67. Nsc56192
68. Zinc8143796
69. Einecs 230-256-0
70. Fusidic Acid For Peak Identification
71. Nsc 56192
72. S3971
73. 16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic Acid
74. Akos005146257
75. Ccg-269829
76. Db02703
77. Ds-3261
78. Lmpr0106040001
79. Ncgc00485232-01
80. (2z)-2-[(17z)-16beta-acetoxy-3alpha,11alpha-dihydroxy-4alpha,8alpha,10,14beta-tetramethyl-5alpha,9beta,13alpha-gonan-17-ylidene]-6-methylhept-5-enoic Acid
81. 29-nordammara-17(20),24-dien-21-oic Acid, 16-(acetyloxy)-3,11-dihydroxy-, (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17z)-
82. 3.alpha.,11.alpha.,16.beta.-trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic Acid 16-acetate
83. C.a.s. 62,602; Diethanolamine Fusidate
84. Cs-0013095
85. F1007
86. C06694
87. D04281
88. 990f063
89. Q259930
90. Q-201141
91. Fusidic Acid, European Pharmacopoeia (ep) Reference Standard
92. Fusidic Acid For Peak Identification, European Pharmacopoeia (ep) Reference Standard
93. (2z)-2-[(3beta,4beta,5alpha,8alpha,9beta,11beta,13alpha,16beta,17z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic Acid
94. (2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-5-heptenoic Acid
95. (2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-4,8,10,14-tetramethyl-3,11-bis(oxidanyl)-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methyl-hept-5-enoic Acid
96. (3alpha,4alpha,8alpha,9beta,11alpha,13alpha,147beta,167beta,17z)-16-(acetyloxy)-3,11-dihydroxy-29-nordammara-17(20),24-dien-21-oic Acid
97. 29-nor-8.alpha.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic Acid, 3.alpha.,11.alpha.,16.beta.-trihydroxy-, 16-acetate, (z)-
98. 29-nor-8alpha,9beta,13alpha,14beta-dammara-17(20),24-dien-21-oic Acid, 3alpha,11alpha,16beta-trihydroxy-, 16-acetate, (z)-
99. 29-nordammara-17(20), 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha.,9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17z)-
100. 29-nordammara-17(20),24-dien-21-oic Acid, 16-(acetyloxy)-3,11-dihydroxy-, (3.alpha.,4.alpha.,8.alpha.,9.beta.,11.alpha.,13.alpha.,14.beta.,16.beta.,17z)
101. 29-nordammara-17(20),24-dien-21-oic Acid, 16-(acetyloxy)-3,11-dihydroxy-, (3a,4a,8a,9b,11a,13a,14b,16b,17z)-
102. 3.alpha.,16.beta.-trihydroxy-29-nor-8.alpha.,9.beta.,13.alpha.,14.beta.-dammara-17(20),24-dien-21-oic Acid 16-acetate
103. 3alpha,11alpha,16beta-trihydroxy-29-nor-8alpha,9beta,13alpha,14beta-dammara-17(20),24-dien-21-oic Acid 16-acetate
| Molecular Weight | 516.7 g/mol |
|---|---|
| Molecular Formula | C31H48O6 |
| XLogP3 | 5.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 516.34508925 g/mol |
| Monoisotopic Mass | 516.34508925 g/mol |
| Topological Polar Surface Area | 104 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 994 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of bacterial infections.
Fusidic acid is a bacteriostatic antibiotic and helps prevent bacterial growth while the immune system clears the infection.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
D - Dermatologicals
D06 - Antibiotics and chemotherapeutics for dermatological use
D06A - Antibiotics for topical use
D06AX - Other antibiotics for topical use
D06AX01 - Fusidic acid
D - Dermatologicals
D09 - Medicated dressings
D09A - Medicated dressings
D09AA - Medicated dressings with antiinfectives
D09AA02 - Fusidic acid
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01X - Other antibacterials
J01XC - Steroid antibacterials
J01XC01 - Fusidic acid
S - Sensory organs
S01 - Ophthalmologicals
S01A - Antiinfectives
S01AA - Antibiotics
S01AA13 - Fusidic acid
Absorption
Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.
Metabolites include dicarboxylic ester/acid, 3-keto fusidic acid, hydroxy fusidic acid, glucuronide fusidic acid and a glycol metabolite.
Approximately 5 to 6 hours in adults.
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
69
PharmaCompass offers a list of Fusidic Acid API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fusidic Acid manufacturer or Fusidic Acid supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fusidic Acid manufacturer or Fusidic Acid supplier.
PharmaCompass also assists you with knowing the Fusidic Acid API Price utilized in the formulation of products. Fusidic Acid API Price is not always fixed or binding as the Fusidic Acid Price is obtained through a variety of data sources. The Fusidic Acid Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fucithalmic manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fucithalmic, including repackagers and relabelers. The FDA regulates Fucithalmic manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fucithalmic API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fucithalmic manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fucithalmic supplier is an individual or a company that provides Fucithalmic active pharmaceutical ingredient (API) or Fucithalmic finished formulations upon request. The Fucithalmic suppliers may include Fucithalmic API manufacturers, exporters, distributors and traders.
click here to find a list of Fucithalmic suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fucithalmic DMF (Drug Master File) is a document detailing the whole manufacturing process of Fucithalmic active pharmaceutical ingredient (API) in detail. Different forms of Fucithalmic DMFs exist exist since differing nations have different regulations, such as Fucithalmic USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fucithalmic DMF submitted to regulatory agencies in the US is known as a USDMF. Fucithalmic USDMF includes data on Fucithalmic's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fucithalmic USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fucithalmic suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Fucithalmic Drug Master File in Korea (Fucithalmic KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Fucithalmic. The MFDS reviews the Fucithalmic KDMF as part of the drug registration process and uses the information provided in the Fucithalmic KDMF to evaluate the safety and efficacy of the drug.
After submitting a Fucithalmic KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Fucithalmic API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Fucithalmic suppliers with KDMF on PharmaCompass.
A Fucithalmic CEP of the European Pharmacopoeia monograph is often referred to as a Fucithalmic Certificate of Suitability (COS). The purpose of a Fucithalmic CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Fucithalmic EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Fucithalmic to their clients by showing that a Fucithalmic CEP has been issued for it. The manufacturer submits a Fucithalmic CEP (COS) as part of the market authorization procedure, and it takes on the role of a Fucithalmic CEP holder for the record. Additionally, the data presented in the Fucithalmic CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Fucithalmic DMF.
A Fucithalmic CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Fucithalmic CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Fucithalmic suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fucithalmic as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fucithalmic API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fucithalmic as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fucithalmic and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fucithalmic NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fucithalmic suppliers with NDC on PharmaCompass.
Fucithalmic Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fucithalmic GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fucithalmic GMP manufacturer or Fucithalmic GMP API supplier for your needs.
A Fucithalmic CoA (Certificate of Analysis) is a formal document that attests to Fucithalmic's compliance with Fucithalmic specifications and serves as a tool for batch-level quality control.
Fucithalmic CoA mostly includes findings from lab analyses of a specific batch. For each Fucithalmic CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fucithalmic may be tested according to a variety of international standards, such as European Pharmacopoeia (Fucithalmic EP), Fucithalmic JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fucithalmic USP).
